PMID- 35316815
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221121
IS  - 1423-0194 (Electronic)
IS  - 0028-3835 (Print)
IS  - 0028-3835 (Linking)
VI  - 112
IP  - 11
DP  - 2022
TI  - The Impact of COVID-19 and Vaccine on the Human Nervous System.
PG  - 1046-1057
LID - 10.1159/000524234 [doi]
AB  - The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory 
      syndrome coronavirus 2 (SARS-CoV-2), has precipitated a global health crisis of 
      unprecedented proportions. Due to its severe impact, multiple COVID-19 vaccines 
      are being developed, approved, and manufactured rapidly. However, some serious 
      adverse events (AEs) were reported after the application of them, significantly 
      increasing concerns about the safety and efficacy of the vaccines and doubts 
      about the necessity of vaccination. Particularly, previous vaccination campaigns 
      have shown us that partial vaccination can induce neurologic AEs. Herein, we 
      discuss in depth the involvement of the nervous system during SARS-CoV-2 
      infection or after vaccination. On the one hand, COVID-19 could pose an enormous 
      threat to human neurological health through direct infection and indirect 
      neurotoxicity effects. On the other hand, our review indicated that only a few 
      serious neurological AEs following vaccination occurred and among which headache 
      was the most common. Moreover, some neurological AEs do not seem to be related to 
      vaccination. Of course, the causal relationships between several vaccines and AEs 
      are considered plausible, and it is not doubtful that these AEs should be taken 
      seriously by clinicians in assessing the potential risks and benefits of 
      vaccinations in special populations. Nevertheless, in the case of the rapid 
      spread of COVID-19, the potential side effects of vaccination on the nervous 
      system should be compared with adverse COVID-19 outcomes rather than being 
      considered alone. Thus, it is obviously a wise option to be vaccinated instead of 
      suffering from serious adverse symptoms of virus infection.
CI  - (c) 2022 S. Karger AG, Basel.
FAU - Chen, Fei
AU  - Chen F
AD  - Department of Physiology, Jining Medical University, Jining, China.
FAU - Cao, Pingdong
AU  - Cao P
AD  - Department of Physiology, Jining Medical University, Jining, China.
FAU - Liu, Huimin
AU  - Liu H
AD  - Department of Physiology, Jining Medical University, Jining, China.
FAU - Cai, Dechen
AU  - Cai D
AD  - Department of Physiology, Jining Medical University, Jining, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220322
PL  - Switzerland
TA  - Neuroendocrinology
JT  - Neuroendocrinology
JID - 0035665
RN  - 0 (Influenza Vaccines)
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (AIDS Vaccines)
RN  - 0 (BCG Vaccine)
RN  - 0 (Diphtheria-Tetanus Vaccine)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (Respiratory Syncytial Virus Vaccines)
RN  - 0 (SAIDS Vaccines)
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Humans
MH  - *Influenza Vaccines
MH  - *COVID-19/prevention & control
MH  - Diphtheria-Tetanus-Pertussis Vaccine
MH  - COVID-19 Vaccines/adverse effects
MH  - *AIDS Vaccines
MH  - BCG Vaccine
MH  - Diphtheria-Tetanus Vaccine
MH  - Measles-Mumps-Rubella Vaccine
MH  - *Respiratory Syncytial Virus Vaccines
MH  - *SAIDS Vaccines
MH  - SARS-CoV-2
MH  - Nervous System
MH  - *Papillomavirus Vaccines
PMC - PMC9148879
OTO - NOTNLM
OT  - AZD1222
OT  - Bell's palsy
OT  - COVID-19 vaccines
OT  - Guillain-Barre syndrome
OT  - Neurological adverse events
OT  - Severe acute respiratory syndrome coronavirus 2
OT  - mRNA vaccine
EDAT- 2022/03/23 06:00
MHDA- 2022/10/26 06:00
PMCR- 2022/03/22
CRDT- 2022/03/22 20:10
PHST- 2021/10/17 00:00 [received]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/03/22 20:10 [entrez]
PHST- 2022/03/22 00:00 [pmc-release]
AID - 000524234 [pii]
AID - nen-0001 [pii]
AID - 10.1159/000524234 [doi]
PST - ppublish
SO  - Neuroendocrinology. 2022;112(11):1046-1057. doi: 10.1159/000524234. Epub 2022 Mar 
      22.